Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Theravance

- PMLiVE

J&J’s Spravato breaks depression drought at FDA

The esketamine nasal spray is the first new-mechanism antidepressant to be licensed in decades

- PMLiVE

J&J bolsters gene therapy unit with $100m MeiraGTx deal

Licenses two inherited retinal disorder candidates

- PMLiVE

Imbruvica and Gazyvo approved in first non-chemo CLL use

Further boost for blockbuster leukaemia drug

- PMLiVE

Morphosys’ Darzalex patent challenge hits a hurdle

Genmab and J&J's myeloma drug is a blockbuster

- PMLiVE

J&J earnings top expectations, but feels the squeeze in US

Blockbuster Xarelto declines 14% due to US competition

- PMLiVE

Blow for J&J as court refuses to overturn talc verdict

Reuters and company at loggerheads over veracity of claims

- PMLiVE

J&J takes on Novartis’ Cosentyx with head-to-head psoriasis trial

The majority of patients on Tremfya achieved at least a 90% improvement from PASI score

- PMLiVE

Dutch biotech Argenx claims $1.8bn licensing deal with J&J

Deal centres around blood cancer candidate cusatuzumab

- PMLiVE

Generic threat looms to J&J’s blockbuster Zytiga in US

Impact could also be felt by Pfizer

- PMLiVE

Janssen submits esketamine in Europe for treatment resistant depression

Fast-acting drug would be first new treatment for refractory disease in 50 years

- PMLiVE

Janssen’s single tablet Symtuza gains NHS England funding 

Janssen and Gilead combination first to reach patients

- PMLiVE

J&J files ‘breakthrough’ bladder cancer drug in US

Needed as most patients don't respond to checkpoint inhibitors

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links